Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes.

Molecular and cellular neurosciences

Koranyi L, Bourey RE, James D, Mueckler M, Fiedorek FT, Permutt MA.
PMID: 19912805
Mol Cell Neurosci. 1991 Jun;2(3):244-52. doi: 10.1016/1044-7431(91)90051-o.

Steady-state levels of the major glucose transporter gene (GLUT-1) of the brain were evaluated under three conditions that induced chronic changes in plasma glucose and insulin in adult rats: (i) repeated injection of insulin for 5 days, resulting in...

Cite
Koranyi L, Bourey RE, James D, et al. Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. Mol Cell Neurosci. 1991;2(3):244-52doi: 10.1016/1044-7431(91)90051-o.
Koranyi, L., Bourey, R. E., James, D., Mueckler, M., Fiedorek, F. T., & Permutt, M. A. (1991). Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. Molecular and cellular neurosciences, 2(3), 244-52. https://doi.org/10.1016/1044-7431(91)90051-o
Koranyi, L, et al. "Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes." Molecular and cellular neurosciences vol. 2,3 (1991): 244-52. doi: https://doi.org/10.1016/1044-7431(91)90051-o
Koranyi L, Bourey RE, James D, Mueckler M, Fiedorek FT, Permutt MA. Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. Mol Cell Neurosci. 1991 Jun;2(3):244-52. doi: 10.1016/1044-7431(91)90051-o. PMID: 19912805.
Copy Download .nbib Format: NLM
Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary.

Clinical and experimental gastroenterology

Fehnel S, Fiedorek FT, Nelson L, DiBenedetti D, Spence S, Carson RT.
PMID: 30863134
Clin Exp Gastroenterol. 2019 Feb 22;12:93-103. doi: 10.2147/CEG.S184016. eCollection 2019.

BACKGROUND: Diabetic gastroparesis (DG) is defined as delayed gastric emptying with associated gastrointestinal symptoms, without mechanical obstruction. Patient-reported symptoms are critical for diagnosis and evaluation of treatment benefit in DG. The Diabetic Gastroparesis Symptom Severity Diary (DGSSD), a new...

Cite
Fehnel S, Fiedorek FT, Nelson L, et al. Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. Clin Exp Gastroenterol. 2019;12:93-103doi: 10.2147/CEG.S184016.
Fehnel, S., Fiedorek, F. T., Nelson, L., DiBenedetti, D., Spence, S., & Carson, R. T. (2019). Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. Clinical and experimental gastroenterology, 1293-103. https://doi.org/10.2147/CEG.S184016
Fehnel, Sheri, et al. "Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary." Clinical and experimental gastroenterology vol. 12 (2019): 93-103. doi: https://doi.org/10.2147/CEG.S184016
Fehnel S, Fiedorek FT, Nelson L, DiBenedetti D, Spence S, Carson RT. Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. Clin Exp Gastroenterol. 2019 Feb 22;12:93-103. doi: 10.2147/CEG.S184016. eCollection 2019. PMID: 30863134; PMCID: PMC6390855.
Copy Download .nbib Format: NLM
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.

Nature medicine

Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MS.
PMID: 34873344
Nat Med. 2021 Dec 06; doi: 10.1038/s41591-021-01584-3. Epub 2021 Dec 06.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) injected periodically have been shown to not increase and, for some members of this class, decrease the risk of cardiovascular events. The cardiovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA...

Cite
Ruff CT, Baron M, Im K, et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2021;doi: 10.1038/s41591-021-01584-3.
Ruff, C. T., Baron, M., Im, K., O'Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2021). Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nature medicine, . https://doi.org/10.1038/s41591-021-01584-3
Ruff, Christian T, et al. "Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial." Nature medicine vol. (2021). doi: https://doi.org/10.1038/s41591-021-01584-3
Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2021 Dec 06; doi: 10.1038/s41591-021-01584-3. Epub 2021 Dec 06. PMID: 34873344.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries